Doximity stock
Price history
−38.11% over the period1 year: from $46.42 (November 20, 2025) to $28.73 (November 20, 2026), −38.11%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | $28.73 |
| October 30, 2026 | $32.76 |
| September 30, 2026 | $28.34 |
| August 31, 2026 | $26.71 |
| July 31, 2026 | $20.91 |
| June 30, 2026 | $20.74 |
| May 29, 2026 | $21.40 |
| April 30, 2026 | $24.44 |
| March 31, 2026 | $23.30 |
| February 27, 2026 | $24.53 |
| January 30, 2026 | $37.47 |
| December 31, 2025 | $44.28 |
| November 28, 2025 | $51.44 |
| November 20, 2025 | $46.42 |
At a glance
The company
Digital platform offering clinical content, workflow tools and networking features for medical professionals in the United States
Latest results
Quarter to September 30, 2026 · EPS $0.36 (estimate $0.35)
Next event
TickerLandia's take on Doximity
- Cheaper than usual relative to earnings: P/E on the latest fiscal year 29 vs a median of 52 over its last 5 fiscal years.
- Strong point: Financial strength (93/100 in its group). Weak point: Growth (36/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−44.58% from the 52-week high
Analysts · 21 analysts
Average target$31.50+9.64% vs. price
Buy 8 · Hold 11 · Sell 2 · Hold
TickerLandia Fingerprint: Doximity
Compared with similar companies: very high financial strength and very high profitability.
Financials and price compared with 44 companies in related industries (health_services), worldwide. Momentum and risk compared with 888 North American stocks.
Pricehigh75
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 41.0 84 Forward P/E 18.5 55 EV/EBITDA 23.6 82 Price/book 5.52 71 Price/sales 7.75 85 Profitabilityvery high85
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 86.8% 94 Operating margin 27.1% 94 Net margin 21.1% 92 ROE 13.8% 55 ROA 9.5% 90 Earnings stabilitylow39
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 3.9% 19 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 59 Growthlow36
How fast revenue and earnings are growing.
Metric Value Position in group Revenue growth (year over year) +3.60% 25 Earnings growth (year over year) −41.90% 6 Average revenue growth (3 years) +15.45% 76 Financial strengthvery high93
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Debt/equitycounts in reverse: lower means more financial strength 0.01 92 Net debt/EBITDAcounts in reverse: lower means more financial strength · more cash than debt −0.91 94 Current ratio 6.37 94 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumstrong71
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +22.47% 91 Relative strength (6 months) +55.60% 97 Distance from 200-day average +14.60% 89 1-year return −38.11% 6 Riskhigh70
How much the price swings.
Metric Value Position in group Maximum drawdown (12 months) 65.0% 96 Volatility (60 days) 45.2% 68 Beta (1 year) 0.63 47
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Doximity is cheaper than in the past and cheaper than similar companies
On the latest fiscal year's earnings (2026), Doximity's P/E today is 29.3, below the median of its last 5 fiscal years (52.3; between 23.8 and 74.4 from 2022 to 2026). Doximity's Forward P/E: 18.5, −29% against the median of a group of 5 similar companies (26.0).
Compared with 5 similar companies
| Metric | Doximity | Position in the group | Band |
|---|---|---|---|
| Forward P/E | 18.5 | Low | |
| Operating margin | 27.1% | Middle | |
| ROE | 13.8% | Middle | |
| Debt/equity | 0.01 | Low | |
| Price/book | 5.52 | Middle |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Doximity. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$174.54M
Latest quarter · Q3 2026
Net income
$34.73M
Latest quarter · Q3 2026
Quarterly net margin
19.9%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- $5.13B
- P/E
- 39.9
- EPS
- $0.72
- Volume
- 2.38M
- Daily trading
- €69.77M
- Dividend yield
- 0.00%
How Doximity is changing
All resultsRevenue grew 25.5% a year on average over the last 5 years
Operating margin rose from 30.0% to 34.4%
Profits turn into cash: free cash flow equal to 138% of net income
Returns
Doximity returns
$1,000 invested in Doximity 5 years ago, on November 22, 2021, would be worth $486 today: −51.35% in total, −13.44% per year. This is the price return only: dividends are excluded.
| Period | Doximity | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | −13.85% | −10.40% | $861 |
| 6 months | +44.66% | −7.03% | $1,447 |
| Year to date | −35.12% | +0.95% | $649 |
| 1 year | −38.11% | +5.68% | $619 |
| 3 years | +17.65% | +51.96% | $1,176 |
| 5 years | −51.35% | +47.57% | $486 |
Over the last 6 months it has done better than 90% of the stocks in the Healthcare sector.
Price only, without dividends. Calculate your investment
The chart in detail
Doximity: technical analysis
Doximity shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 71.8% below its all-time closing high ($102.02, September 10, 2021).
- Trend
- No clear trend
- RSI (14 sessions)
- 35
- Between 30 and 70
- vs 200-session average
- +14.60%
Active signals
Close below the low of the previous 20 sessions.
since November 19, 2026
Support and resistance
Price areas where Doximity has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$46.70+62.56%2 touches, last on January 6, 2026
- Resistance$43.23+50.47%2 touches, last on January 2, 2026
- Last price$28.73
- Support$27.15−5.52%4 touches, last on September 22, 2026
- Support$25.46−11.37%3 touches, last on September 28, 2026
- Support$23.89−16.83%8 touches, last on September 9, 2026
Volatility and risk
Over the last year it has moved less than the S&P 500.
- Beta (1 year) vs S&P 500
- 0.63
- Volatility (60 sessions, annualised)
- 45.2%
- Largest fall in the last year
- −65.05%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Doximity: seasonality
Average monthly price change over 6 years
Over the last 6 years, the strongest month for Doximity has been August: +11.42% on average, positive in 4 years out of 6. The weakest has been March: −9.24% on average, positive in 0 years out of 5. November, the current month, has been positive in 3 years out of 5 (+8.90% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | −2.51% | −3.89% | 2 of 5 |
| February | +3.90% | +4.75% | 3 of 5 |
| March | −9.24% | −5.01% | 0 of 5 |
| April | −3.36% | −1.98% | 2 of 5 |
| May | −7.10% | −12.24% | 1 of 5 |
| June | +5.20% | +0.87% | 3 of 5 |
| July | +4.94% | +2.92% | 5 of 6 |
| August | +11.42% | +21.69% | 4 of 6 |
| September | 0.00% | −1.42% | 3 of 6 |
| October | −4.74% | −6.99% | 1 of 6 |
| November | +8.90% | +13.80% | 3 of 5 |
| December | −3.95% | −1.27% | 2 of 5 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Doximity and its competitors
Known to doctors as the Doximity platform, the company runs a professional network where medical staff follow clinical research, video summaries and peer updates in a personalized feed, and where drug makers and health systems also place sponsored content. Its newer tools include Ask, an AI assistant for finding evidence-based answers during patient care, Scribe, an AI tool that drafts clinical notes, and AMiON for on-call scheduling. Its clients range from nurse practitioners and medical students to pharmaceutical manufacturers and hospital networks, and its activity is focused on the United States.
- Headquarters
- San Francisco, United States
- Employees
- 880
- Founded
- 2010
- Chief executive
- Jeffrey Tangney
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| DoximityDOCS | $5.13B | 27.1% | 39.9 | +44.66% |
| Tempus AITEM | $9.86B | -18.5% | — | +17.79% |
| Veeva SystemsVEEV | $43.1B | 29.9% | 43.6 | +61.38% |
| M32413 | $7.04B | 19.5% | 24.4 | +19.18% |
| XtalPi Holdings2228 | $3B | -124.6% | — | −39.24% |
| Pro MedicusPME | $13.08B | 74.9% | 76.0 | +45.89% |
Same industry or related industries, similar size. Compare Doximity with its competitors · Full profile
